OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

OKYO Pharma Limited announces that Chief Scientific Officer Raj Patil purchased additional shares, increasing his total holdings ahead of the company's planned Phase 3 pivotal clinical trial for urcosimod targeting neuropathic corneal pain. This insider buying signals confidence in the company’s clinical pipeline and growth prospects.

OKYO

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Raj Patil, Chief Scientific Officer, bought 3,363 shares at $1.49 each, increasing total holdings to 20,030 shares.
OKYO Pharma is preparing to initiate a global Phase 3 clinical trial enrolling approximately 111 patients for urcosimod in the second half of 2026.
The company focuses on treatments for neuropathic corneal pain and anterior segment eye diseases, areas within the biopharmaceutical and ophthalmology sectors.

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company’s ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares.

About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com

Risks

Clinical trial outcomes are uncertain and could negatively impact stock and development trajectory if results are unfavorable.
Insider buying, while positive, does not guarantee success and may be perceived as limited only to internal confidence.
Market reception of novel therapies for neuropathic corneal pain is uncertain, affecting commercialization potential and investor sentiment.

Menu

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

Key Points

Risks

More from Press Releases